IQVIA Holdings Inc.
IQVIA Holdings Inc. (IQV) is a global provider of clinical research services, real-world data, and analytics to the life sciences industry. It operates as a contract research organisation (CRO) delivering clinical trial management, regulatory support and commercial analytics, combining operational trial capabilities with large proprietary healthcare datasets and technology platforms. The business benefits from structural trends: pharmaceutical and biotech firms outsourcing R&D, rising demand for real-world evidence and use of analytics/AI to shorten time-to-market. With a market capitalisation around $37.2bn, IQVIA’s scale and global footprint are competitive advantages, though growth depends on contract wins, regulatory trends and continued tech investment. Key risks include competitive pressure, project concentration, regulatory and data-privacy challenges, and sensitivity to R&D budgets. This summary is for general educational purposes only and not personal investment advice; values can fall as well as rise and investors should check current filings and suitability for their circumstances.
Why It's Moving
Analysts Boost IQVIA Targets on Robust Recovery Outlook into 2026
IQVIA Holdings draws fresh bullish attention as Stifel and Deutsche Bank hike price targets, spotlighting the healthcare analytics leader's strong positioning amid industry recovery. Investors are responding positively to management insights signaling steady demand growth in R&D and data services.
- Stifel raised its price target to $273 from $254 with a Buy rating after management meetings, forecasting 6%-9% medium-term revenue growth as recovery pace firms up into 2026[3].
- Deutsche Bank upped its target to $250 from $235, maintaining Buy amid consensus Moderate Buy vibe with 19 Buy ratings and average target implying 12%+ upside[1][6].
- Technical momentum builds with shares near 52-week highs, positive moving averages, and six recent upward earnings revisions for 2025 to $11.90 EPS[1][4].
Analysts Boost IQVIA Targets on Robust Recovery Outlook into 2026
IQVIA Holdings draws fresh bullish attention as Stifel and Deutsche Bank hike price targets, spotlighting the healthcare analytics leader's strong positioning amid industry recovery. Investors are responding positively to management insights signaling steady demand growth in R&D and data services.
- Stifel raised its price target to $273 from $254 with a Buy rating after management meetings, forecasting 6%-9% medium-term revenue growth as recovery pace firms up into 2026[3].
- Deutsche Bank upped its target to $250 from $235, maintaining Buy amid consensus Moderate Buy vibe with 19 Buy ratings and average target implying 12%+ upside[1][6].
- Technical momentum builds with shares near 52-week highs, positive moving averages, and six recent upward earnings revisions for 2025 to $11.90 EPS[1][4].
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying IQVIA's stock with a target price of $253.7, indicating strong growth potential.
Financial Health
IQVIA is performing well with strong revenue, profits, and cash flow generation capabilities.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring IQV
Pharmaceutical Policy Shift Explained | Pricing Models
The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.
Published: October 12, 2025
Explore BasketPharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Published: August 19, 2025
Explore BasketNavigating U.S. Drug Price Reforms
The White House is demanding major pharmaceutical companies slash U.S. drug prices, creating significant market volatility and threatening industry profits. This creates a potential opening for companies that offer cost-saving alternatives, such as generic drug makers and healthcare service providers.
Published: August 5, 2025
Explore BasketPediatric Vaccine Rollout
This carefully selected group of stocks represents companies positioned to benefit from the full FDA approval of COVID-19 vaccines for at-risk children. Our professional analysts have identified opportunities across the entire value chain, from vaccine manufacturers to healthcare providers and clinical research organizations.
Published: July 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Research Demand
Outsourcing of drug development supports recurring project flow and long contract cycles, though revenues can vary with client R&D budgets and competitive pressures.
Global Footprint
A wide international presence helps win multinational trials and diversify revenues, but exposes the company to regulatory and currency headwinds.
Data and Analytics
Proprietary datasets and analytics platforms are differentiators as life sciences firms seek real‑world evidence and AI‑driven insights, though data governance is an ongoing risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
